Molecular pharming

Paul, Mathew; Dolleweerd, Craig J. van; Drake, Pascal M. W.; Reljić, Rajko; Thangaraj, Harry; Barbi, Tommaso; Stylianou, Elena; Pepponi, Ilaria; Both, Leonard; Hehle, Verena; Madeira, Luisa; Inchakalody, Varghese; Ho, Sammy; Guerra, Thais; K‐C., Julian

doi:10.4161/hv.7.3.14456

Cited by 43 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low production costs, ability of plants to assemble and modify multimeric proteins such as mAbs, and ease of scalability make plants a viable platform for production of mAbs to replace RIG [24, 25]. …”

mentioning

confidence: 99%

Engineering, Expression in Transgenic Plants and Characterisation of E559, a Rabies Virus-Neutralising Monoclonal Antibody

Dolleweerd

Teh

Banyard

et al. 2014

The Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Rabies post-exposure prophylaxis (PEP) currently comprises administration of rabies vaccine together with rabies immunoglobulin (RIG) of either equine or human origin. In the developing world, RIG preparations are expensive, often in short supply, and of variable efficacy. Therefore, we are seeking to develop a monoclonal antibody cocktail to replace RIG. Here, we describe the cloning, engineering and production in plants of a candidate monoclonal antibody (E559) for inclusion in such a cocktail. The murine constant domains of E559 were replaced with human IgG1κ constant domains and the resulting chimeric mouse-human genes were cloned into plant expression vectors for stable nuclear transformation of Nicotiana tabacum. The plant-expressed, chimeric antibody was purified and biochemically characterized, was demonstrated to neutralize rabies virus in a fluorescent antibody virus neutralization assay, and conferred protection in a hamster challenge model.

show abstract

mentioning

confidence: 99%

Engineering, Expression in Transgenic Plants and Characterisation of E559, a Rabies Virus-Neutralising Monoclonal Antibody

Dolleweerd

Teh

Banyard

et al. 2014

The Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…[33][34][35][36][37][38][39][40] Several previous studies have shown plant produced HA is effective in mouse and ferret models of influenza challenge, but always require at least two immunizations with adjuvant to stimulate HAI titers or protective immunity. 18,20,41 Disappointing results from a Phase I clinical trial reported only 5-10% seroconversion after 90 µg dosing with an HA vaccine, irrespective of adjuvant co-formulation, 42 or may require 2 doses of alum-adjuvanted vaccine for clinically significant immune protection.…”

Section: Discussionmentioning

confidence: 99%

Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge

Mallajosyula

Hiatt

Hume

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Molecular farming using plants or plant cell lines as a green factory to produce vaccines and biopharmaceuticals has also made considerable progress with commercially released plant-made therapeutic proteins, and a number of vaccines and therapeutic proteins are undergoing clinical trials or are in the pipeline to be approved (Yusibov et al 2011; http://www.genengnews.com/gen-news-highlights/); however, it has encountered the same regulatory constraints as other GM crops. Under the current regulatory requirements, it’s estimated that it takes on average 7-10 million euros to approve a GM crop for cultivation (Paul et al 2011). …”

Section: Regulatory Constraintsmentioning

confidence: 99%

How can plant genetic engineering contribute to cost-effective fish vaccine development for promoting sustainable aquaculture?

et al. 2013

View full text Add to dashboard Cite

Aquaculture, the fastest growing food-producing sector, now accounts for nearly 50 % of the world’s food fish (FAO in The state of world fisheries and aquaculture. FAO, Rome, 2010). The global aquaculture production of food fish reached 62.7 million tonnes in 2011 and is continuously increasing with an estimated production of food fish of 66.5 million tonnes in 2012 (a 9.4 % increase in 1 year, FAO, www.fao.org/fishery/topic/16140). Aquaculture is not only important for sustainable protein-based food fish production but also for the aquaculture industry and economy worldwide. Disease prevention is the key issue to maintain a sustainable development of aquaculture. Widespread use of antibiotics in aquaculture has led to the development of antibiotic-resistant bacteria and the accumulation of antibiotics in the environment, resulting in water and soil pollution. Thus, vaccination is the most effective and environmentally-friendly approach to combat diseases in aquaculture to manage fish health. Furthermore, when compared to >760 vaccines against human diseases, there are only about 30 fish vaccines commercially available, suggesting the urgent need for development and cost-effective production of fish vaccines for managing fish health, especially in the fast growing fish farming in Asia where profit is minimal and therefore given high priority. Plant genetic engineering has made significant contributions to production of biotech crops for food, feed, valuable recombinant proteins etc. in the past three decades. The use of plants for vaccine production offers several advantages such as low cost, safety and easy scaling up. To date a large number of plant-derived vaccines, antibodies and therapeutic proteins have been produced for human health, of which a few have been made commercially available. However, the development of animal vaccines in plants, especially fish vaccines by genetic engineering, has not yet been addressed. Therefore, there is a need to exploit plant biotechnology for cost effective fish vaccine development in plants, in particular, edible crops for oral fish vaccines. This review provides insight into (1) the current status of fish vaccine and vaccination in aquaculture, (2) plant biotechnology and edible crops for fish vaccines for oral administration, (3) regulatory constraints and (4) conclusions and future perspectives.

show abstract

Molecular pharming

Cited by 43 publications

References 40 publications

Engineering, Expression in Transgenic Plants and Characterisation of E559, a Rabies Virus-Neutralising Monoclonal Antibody

Engineering, Expression in Transgenic Plants and Characterisation of E559, a Rabies Virus-Neutralising Monoclonal Antibody

Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge

How can plant genetic engineering contribute to cost-effective fish vaccine development for promoting sustainable aquaculture?

Contact Info

Product

Resources

About